 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Notice of FDA Advisory Committee Meeting on February 27, 2001Valganciclovir Hydrochloride Tablets for Treatment of Cytomegalovirus (CMV) Retinitis
February 2, 2001 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! The FDA Antiviral Drugs Advisory Committee will meet on February 27, 2001, to discuss data related to the safety and effectiveness of valganciclovir hydrochloride 450 mg tablets, proposed for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. The drug sponsor is Syntex (USA). This meeting is scheduled to take place from 9:00 a.m. to 5:30 p.m. at the Holiday Inn (the Ballrooms), 2 Montgomery Avenue, Gaithersburg, MD. You can contact the hotel directly at 301.948.8900 for directions or accommodation information. The public is invited and encouraged to attend FDA advisory committee meetings. No registration is required. If you would like to make an oral presentation on February 27, please send the following information to Tara Turner, Pharm. D., Center for Drug Evaluation and Research (HFD-21), 5600 Fishers Lane, Rockville, MD 20857, 301.827.7001, e-mail TurnerT@cder.fda.gov, or by fax to 301.827.6776, by February 20, 2001.
Oral presentations from the public are scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited, depending on the number of speakers. Written information may be submitted to Dr. Turner at the same mailing or e-mail address, or by fax. Written information should also be received before February 20, 2001. For up-to-date information about this meeting, please call the FDA Advisor Committee Information Line, 1.800.741.8138 (301.443.0572 in the Washington D.C. area) and press code 12531. For general information, contact Richard Klein, Office of Special Health Issues, 301.827.4460, or e-mail Rklein@oc.fda.gov. A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!  This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
